Pierre-Marie Duret

Dr. Pierre-Marie Duret

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
PDPierre-Marie Duret
Pierre-Marie Duret
ESEden Sebbag
Eden Sebbag
AMAuriane Mallick
Auriane Mallick
SGSimon Gravier
Simon Gravier
LSLionel Spielmann
Lionel Spielmann
LMLaurent Messer
Laurent Messer

1 September 2023 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
JBJoe Scott Berry
Joe Scott Berry
JTJessica Tarn
Jessica Tarn
JCJohn Casement
John Casement
PDPierre-Marie Duret
Pierre-Marie Duret
LSLauren Scott
Lauren Scott
WNWan-Fai Ng
Wan-Fai Ng
Objectives Stratification approaches are vital to address clinical heterogeneity in Sjogren’s syndrome (SS). We previously described that the Newcastle Sjogren’s Stratification Tool (NSST) identified four distinct clinical subtypes of SS. We performed proteomic and network analysis to analyse the underlying pathobiology and highlight potential therapeutic targets for different SS subtypes. Method We profiled serum proteins using O-link technology of 180 SS subjects. We used 5 O-link proteomics panels which included a total of 454 unique proteins. Network reconstruction was performed using the ARACNE algorithm, with differential expression estimates overlaid on these networks to reveal the key subnetworks of differential expression. Furthermore, data from a phase III trial of tocilizumab in SS were reanalysed by stratifying patients at baseline using NSST. Results Our analysis highlights differential expression of chemokines, cytokines and the major autoantigen TRIM21 between the SS subtypes. Furthermore, we observe differential expression of several transcription factors associated with energy metabolism and redox balance namely APE1/Ref-1, FOXO1, TIGAR and BACH1. The differentially expressed proteins were inter-related in our network analysis, supporting the concept that distinct molecular networks underlie the clinical subtypes of SS. Stratification of patients at baseline using NSST revealed improvement of fatigue score only in the subtype expressing the highest levels of serum IL-6. Conclusions Our data provide clues to the pathways contributing to the glandular and non-glandular manifestations of SS and to potential therapeutic targets for different SS subtypes. In addition, our analysis highlights the need for further exploration of altered metabolism and mitochondrial dysfunction in the context of SS subtypes.

28 July 2023 in Arthritis & Rheumatology
Verified
Journal Article
Open access
PDPierre-Marie Duret
Pierre-Marie Duret
CSCedric Schleiss
Cedric Schleiss
LKLou Kawka
Lou Kawka
NMNicolas Meyer
Nicolas Meyer
TYTao Ye
Tao Ye
Jacques Éric GottenbergJacques Éric Gottenberg
Jacques Éric Gottenberg
Objective: We undertook this study to analyze whole blood gene expression and to investigate the role of B cell genes in primary Sjögren's syndrome–related non‐Hodgkin lymphoma (primary SS‐NHL).Methods: Peripheral whole blood samples were collected from 345 well‐phenotyped patients with primary SS enrolled in the prospective Assessment of Systemic Signs and Evolution in Sjögren's Syndrome (ASSESS) cohort. Transcriptomic analysis was performed using human Clariom S Arrays (Affymetrix). In our primary analysis, we considered patients with incident lymphoma (i‐primary SS‐NHL) as the case group and all patients without lymphoma as the comparison group. In our sensitivity analyses, we considered all patients with primary SS‐NHL, including those with a history of lymphoma (h‐primary SS‐NHL), as the case group and primary SS patients without lymphoma, stratified on their risk factors of lymphoma, as the comparison group.Results: Twenty‐one patients with primary SS‐NHL (including 8 with i‐primary SS‐NHL and 13 h‐primary SS‐NHL) were eligible for transcriptomic analysis; we compared these patients to 324 primary SS controls without lymphoma, including 110 with moderate to severe disease activity and 61 with no risk factor of lymphoma. Functional clustering analyses revealed an enrichment of genes related to innate and adaptive immunity, including B cell–related genes. Bruton's tyrosine kinase (BTK) and a proliferation‐inducing ligand (APRIL) genes were overexpressed before the occurrence of lymphoma in patients with incident lymphoma compared with patients without lymphoma. In sensitivity analyses, BTK was consistently up‐regulated across all comparisons performed. BTK expression was associated with risk of lymphoma on multivariate analyses, which considered 9 validated predictors of lymphoma in primary SS.Conclusion: BTK and APRIL were overexpressed in the peripheral blood of primary SS patients prior to lymphoma. The association between BTK, APRIL, and primary SS‐NHL requires confirmation in other prospective cohorts. image

24 February 2020 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
PDPierre-Marie Duret
Pierre-Marie Duret
NMNicolas Meyer
Nicolas Meyer
ASAlain Saraux
Alain Saraux
VDValérie Devauchelle-Pensec
Valérie Devauchelle-Pensec
RSRaphaele Seror
Raphaele Seror
JGJacques-Eric Gottenberg
Jacques-Eric Gottenberg
Background: To assess the presence of a seasonal effect on fatigue, pain and dryness in primary Sjögren’s syndrome (pSS). Methods: Data (date; visual analogue scales (VAS) for pain, fatigue and dryness) were extracted from three randomised placebo-controlled trials (RCTs) evaluating infliximab (TRIPSS; n = 103 patients), hydroxychloroquine (JOQUER; n = 120 patients) and rituximab (TEARS; n = 120 patients) and from the 5-year follow-up of the ASSESS prospective cohort (n = 395 patients). Data were analysed at each visit for each patient, according to the day, the month of the year and the season. Linear mixed models were used to take into account the repeated structure of the data and to analyse a potential cyclic effect. Results: A total of 744, 584, 848 and 682 pain, fatigue and dryness VASs were collected on 632 subjects in spring, summer, fall and winter, respectively. No significant difference was observed in pain, fatigue and dryness, according to the month of the year or the season (all p values > 0.05). Conclusion: In pSS, seasonality does not affect patient-reported outcomes (PROs) on fatigue, pain and dryness.


14 October 2021 in médecine/sciences
Verified
Journal Article
Open access
PDF file
LMLaurent Messer
Laurent Messer
RFRenaud Felten
Renaud Felten
PDPierre-Marie Duret
Pierre-Marie Duret
JGJacques Eric Gottenberg
Jacques Eric Gottenberg
LWLaura Widawski
Laura Widawski
JSJean Sibilia
Jean Sibilia
La pratique clinique de la médecine nécessite la reconnaissance de la maladie dont souffre le patient par le médecin. Pour cela, celui-ci rationnalise les signes permettant d’isoler une entité réaliste et de la classer dans la nosologie de référence. Contrairement à d’autres pratiques, le modèle biomédical utilise la méthodologie scientifique du recensement, dans une logique de classification pour définir les maladies. Du fait de son processus de simplification, ce modèle néglige les cas de transition ou les cas complexes. En rhumatologie, ce raisonnement classifiant est mis à l’épreuve par le manque d’objectivité et de spécificité des éléments sur lesquels s’appuie le clinicien pour construire le diagnostic, mais aussi par la complexité des mécanismes physiopathologiques des maladies rhumatismales. Ces maladies peuvent en effet se confondre ou s’intriquer, pour aboutir alors à la description de nouvelles entités non envisagées dans les classifications. Nous présentons dans cette revue les difficultés rencontrées au cours de l’exercice de la médecine dans ces contextes, et comment, à partir d’un cas concret, vécu, celles-ci peuvent donner naissance à la proposition d’un nouveau taxon1.